4.18
+0.07(+1.70%)
Currency In USD
| Previous Close | 4.11 |
| Open | 4.09 |
| Day High | 4.26 |
| Day Low | 4.07 |
| 52-Week High | 5.8 |
| 52-Week Low | 2.12 |
| Volume | 1.25M |
| Average Volume | 1.37M |
| Market Cap | 416.84M |
| PE | -6.06 |
| EPS | -0.69 |
| Moving Average 50 Days | 3.77 |
| Moving Average 200 Days | 3.46 |
| Change | 0.07 |
If you invested $1000 in Aquestive Therapeutics, Inc. (AQST) since IPO date, it would be worth $260.44 as of August 18, 2025 at a share price of $4.18. Whereas If you bought $1000 worth of Aquestive Therapeutics, Inc. (AQST) shares 5 years ago, it would be worth $516.05 as of August 18, 2025 at a share price of $4.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
GlobeNewswire Inc.
Aug 14, 2025 10:28 AM GMT
WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science a
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film
GlobeNewswire Inc.
Aug 14, 2025 10:00 AM GMT
Anaphylm launch funding of $75 million committed by RTW, subject to FDA approval of Anaphylm and other conditions Strategic financing will further strengthen the Company’s balance sheet in advance of potential commercialization of Anaphylm for the em
Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
GlobeNewswire Inc.
Aug 04, 2025 11:00 AM GMT
WARREN, N.J., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science a